FlexMedical targeting North America in expansion drive
Eyes on growth (L-R): Donogh Fitzgerald, Murray Whyte and Kevin Fallon of FlexMedical Solutions
Scottish diagnostics specialist FlexMedical Solutions is targeting the North American market after investing £1 million in equipment and creating five R&D labs and new office facilities at its Livingston headquarters.
The company, which offers design, development and manufacturing services to customers in human point-of-care testing, doubled revenue to £3 million in the year to 30 April and is on track for revenue of c.£4.5 million in the current year. It has doubled its headcount to 30 over the past year.
Customers range from start-ups and spin-outs to global corporates, supporting them in the development of tests for the management and diagnosis of multiple diseases and medical conditions, such as respiratory disease, sepsis, kidney disease, heart disease, diabetes, and antimicrobial resistance.
About 70% of revenue comes from outside the UK and the company plans to target the North American market in 2022.